Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

Randall Brand, Erkut Borazanci, Virginia Speare, Beth Dudley, Eve Karloski, Mary Linton B. Peters, Lindsey Stobie, Nathan Bahary, Herbert Zeh, Amer Zureikat, Melissa Hogg, Kenneth Lee, Allan Tsung, John Rhee, James Ohr, Weijing Sun, James Lee, A. James Moser, Kim DeLeonardis, Jill KrejdovskyEmily Dalton, Holly LaDuca, Jill Dolinsky, Arlene Colvin, Cynthia Lim, Mary Helen Black, Nadine Tung

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: The objective of this study was to investigate the prevalence of pathogenic germline variants (PGVs) in 32 cancer susceptibility genes in individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary objective was to evaluate how often PGVs would have been undetected with existing genetic testing criteria. METHODS: From May 2016 through May 2017, this multicenter cohort study enrolled consecutive patients aged 18 to 89 years with histologically confirmed PDAC diagnosed within the previous 12 weeks. Demographics, medical histories, and 3-generation pedigrees were collected from participants who provided samples for germline DNA analysis. RESULTS: Four hundred nineteen patients were deemed eligible, 302 were enrolled, and 298 were included in the final cohort. Clinically actionable variants were reported in 29 PDAC patients (9.7%), with 23 (7.7%) having a PGV associated with an increased risk for PDAC. Six of 23 individuals (26%) with PDAC-associated gene mutations did not meet currently established genetic testing criteria. According to guideline-based genetic testing, only 11 of the 23 PGVs (48%) in known PDAC genes would have been detected. Six additional patients (2%) had PGVs associated with an increased risk for other cancers. CONCLUSIONS: These findings support the significant prevalence of PGVs associated with PDAC and the limitations of current paradigms for selecting patients for genetic testing, and they thereby lend support for universal germline multigene genetic testing in this population.

Original languageEnglish (US)
Pages (from-to)3520-3527
Number of pages8
JournalCancer
Volume124
Issue number17
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Genetic Testing
Adenocarcinoma
Prospective Studies
Neoplasm Genes
Pedigree
Genes
Multicenter Studies
Cohort Studies
Demography
Guidelines
Mutation
DNA
Population
Neoplasms

Keywords

  • genetic susceptibility
  • genetic testing
  • germline mutation
  • hereditary cancer syndromes
  • pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Brand, R., Borazanci, E., Speare, V., Dudley, B., Karloski, E., Peters, M. L. B., ... Tung, N. (2018). Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer, 124(17), 3520-3527. https://doi.org/10.1002/cncr.31628

Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. / Brand, Randall; Borazanci, Erkut; Speare, Virginia; Dudley, Beth; Karloski, Eve; Peters, Mary Linton B.; Stobie, Lindsey; Bahary, Nathan; Zeh, Herbert; Zureikat, Amer; Hogg, Melissa; Lee, Kenneth; Tsung, Allan; Rhee, John; Ohr, James; Sun, Weijing; Lee, James; Moser, A. James; DeLeonardis, Kim; Krejdovsky, Jill; Dalton, Emily; LaDuca, Holly; Dolinsky, Jill; Colvin, Arlene; Lim, Cynthia; Black, Mary Helen; Tung, Nadine.

In: Cancer, Vol. 124, No. 17, 01.09.2018, p. 3520-3527.

Research output: Contribution to journalArticle

Brand, R, Borazanci, E, Speare, V, Dudley, B, Karloski, E, Peters, MLB, Stobie, L, Bahary, N, Zeh, H, Zureikat, A, Hogg, M, Lee, K, Tsung, A, Rhee, J, Ohr, J, Sun, W, Lee, J, Moser, AJ, DeLeonardis, K, Krejdovsky, J, Dalton, E, LaDuca, H, Dolinsky, J, Colvin, A, Lim, C, Black, MH & Tung, N 2018, 'Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma', Cancer, vol. 124, no. 17, pp. 3520-3527. https://doi.org/10.1002/cncr.31628
Brand R, Borazanci E, Speare V, Dudley B, Karloski E, Peters MLB et al. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer. 2018 Sep 1;124(17):3520-3527. https://doi.org/10.1002/cncr.31628
Brand, Randall ; Borazanci, Erkut ; Speare, Virginia ; Dudley, Beth ; Karloski, Eve ; Peters, Mary Linton B. ; Stobie, Lindsey ; Bahary, Nathan ; Zeh, Herbert ; Zureikat, Amer ; Hogg, Melissa ; Lee, Kenneth ; Tsung, Allan ; Rhee, John ; Ohr, James ; Sun, Weijing ; Lee, James ; Moser, A. James ; DeLeonardis, Kim ; Krejdovsky, Jill ; Dalton, Emily ; LaDuca, Holly ; Dolinsky, Jill ; Colvin, Arlene ; Lim, Cynthia ; Black, Mary Helen ; Tung, Nadine. / Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. In: Cancer. 2018 ; Vol. 124, No. 17. pp. 3520-3527.
@article{fe9bdfb5e78f4434b7d87736726f9328,
title = "Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma",
abstract = "BACKGROUND: The objective of this study was to investigate the prevalence of pathogenic germline variants (PGVs) in 32 cancer susceptibility genes in individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary objective was to evaluate how often PGVs would have been undetected with existing genetic testing criteria. METHODS: From May 2016 through May 2017, this multicenter cohort study enrolled consecutive patients aged 18 to 89 years with histologically confirmed PDAC diagnosed within the previous 12 weeks. Demographics, medical histories, and 3-generation pedigrees were collected from participants who provided samples for germline DNA analysis. RESULTS: Four hundred nineteen patients were deemed eligible, 302 were enrolled, and 298 were included in the final cohort. Clinically actionable variants were reported in 29 PDAC patients (9.7{\%}), with 23 (7.7{\%}) having a PGV associated with an increased risk for PDAC. Six of 23 individuals (26{\%}) with PDAC-associated gene mutations did not meet currently established genetic testing criteria. According to guideline-based genetic testing, only 11 of the 23 PGVs (48{\%}) in known PDAC genes would have been detected. Six additional patients (2{\%}) had PGVs associated with an increased risk for other cancers. CONCLUSIONS: These findings support the significant prevalence of PGVs associated with PDAC and the limitations of current paradigms for selecting patients for genetic testing, and they thereby lend support for universal germline multigene genetic testing in this population.",
keywords = "genetic susceptibility, genetic testing, germline mutation, hereditary cancer syndromes, pancreatic ductal adenocarcinoma",
author = "Randall Brand and Erkut Borazanci and Virginia Speare and Beth Dudley and Eve Karloski and Peters, {Mary Linton B.} and Lindsey Stobie and Nathan Bahary and Herbert Zeh and Amer Zureikat and Melissa Hogg and Kenneth Lee and Allan Tsung and John Rhee and James Ohr and Weijing Sun and James Lee and Moser, {A. James} and Kim DeLeonardis and Jill Krejdovsky and Emily Dalton and Holly LaDuca and Jill Dolinsky and Arlene Colvin and Cynthia Lim and Black, {Mary Helen} and Nadine Tung",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/cncr.31628",
language = "English (US)",
volume = "124",
pages = "3520--3527",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "17",

}

TY - JOUR

T1 - Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

AU - Brand, Randall

AU - Borazanci, Erkut

AU - Speare, Virginia

AU - Dudley, Beth

AU - Karloski, Eve

AU - Peters, Mary Linton B.

AU - Stobie, Lindsey

AU - Bahary, Nathan

AU - Zeh, Herbert

AU - Zureikat, Amer

AU - Hogg, Melissa

AU - Lee, Kenneth

AU - Tsung, Allan

AU - Rhee, John

AU - Ohr, James

AU - Sun, Weijing

AU - Lee, James

AU - Moser, A. James

AU - DeLeonardis, Kim

AU - Krejdovsky, Jill

AU - Dalton, Emily

AU - LaDuca, Holly

AU - Dolinsky, Jill

AU - Colvin, Arlene

AU - Lim, Cynthia

AU - Black, Mary Helen

AU - Tung, Nadine

PY - 2018/9/1

Y1 - 2018/9/1

N2 - BACKGROUND: The objective of this study was to investigate the prevalence of pathogenic germline variants (PGVs) in 32 cancer susceptibility genes in individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary objective was to evaluate how often PGVs would have been undetected with existing genetic testing criteria. METHODS: From May 2016 through May 2017, this multicenter cohort study enrolled consecutive patients aged 18 to 89 years with histologically confirmed PDAC diagnosed within the previous 12 weeks. Demographics, medical histories, and 3-generation pedigrees were collected from participants who provided samples for germline DNA analysis. RESULTS: Four hundred nineteen patients were deemed eligible, 302 were enrolled, and 298 were included in the final cohort. Clinically actionable variants were reported in 29 PDAC patients (9.7%), with 23 (7.7%) having a PGV associated with an increased risk for PDAC. Six of 23 individuals (26%) with PDAC-associated gene mutations did not meet currently established genetic testing criteria. According to guideline-based genetic testing, only 11 of the 23 PGVs (48%) in known PDAC genes would have been detected. Six additional patients (2%) had PGVs associated with an increased risk for other cancers. CONCLUSIONS: These findings support the significant prevalence of PGVs associated with PDAC and the limitations of current paradigms for selecting patients for genetic testing, and they thereby lend support for universal germline multigene genetic testing in this population.

AB - BACKGROUND: The objective of this study was to investigate the prevalence of pathogenic germline variants (PGVs) in 32 cancer susceptibility genes in individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary objective was to evaluate how often PGVs would have been undetected with existing genetic testing criteria. METHODS: From May 2016 through May 2017, this multicenter cohort study enrolled consecutive patients aged 18 to 89 years with histologically confirmed PDAC diagnosed within the previous 12 weeks. Demographics, medical histories, and 3-generation pedigrees were collected from participants who provided samples for germline DNA analysis. RESULTS: Four hundred nineteen patients were deemed eligible, 302 were enrolled, and 298 were included in the final cohort. Clinically actionable variants were reported in 29 PDAC patients (9.7%), with 23 (7.7%) having a PGV associated with an increased risk for PDAC. Six of 23 individuals (26%) with PDAC-associated gene mutations did not meet currently established genetic testing criteria. According to guideline-based genetic testing, only 11 of the 23 PGVs (48%) in known PDAC genes would have been detected. Six additional patients (2%) had PGVs associated with an increased risk for other cancers. CONCLUSIONS: These findings support the significant prevalence of PGVs associated with PDAC and the limitations of current paradigms for selecting patients for genetic testing, and they thereby lend support for universal germline multigene genetic testing in this population.

KW - genetic susceptibility

KW - genetic testing

KW - germline mutation

KW - hereditary cancer syndromes

KW - pancreatic ductal adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85052815069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052815069&partnerID=8YFLogxK

U2 - 10.1002/cncr.31628

DO - 10.1002/cncr.31628

M3 - Article

C2 - 30067863

AN - SCOPUS:85052815069

VL - 124

SP - 3520

EP - 3527

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 17

ER -